Preprint Watch 2026-05-22: 1 Clinical Failures Flagged for EGFR | Claidex

Q: Why was this EGFR preprint flagged?

1 prior Claidex failure claim matched the target-disease mechanism. The preprint identifies a PKCα-dependent stem-like subpopulation as the root of EGFR TKI-tolerant persisters in NSCLC, with the implication that osimertinib-driven persister cells survive through a non-mutational, plastic state rather than C797S-style on-target resistance. This refines, but does not contradict, the mechanistic story underlying bg-60366-egfr-cdac-nsclc-strategic-shutdown: an EGFR degrader still has to clear persister populations that do not require an EGFR-binding pocket, and any post-osimertinib program should pre-specify persister-state biomarkers in dose expansion.

Claidex Preprint Watch

doi:10.64898/2026.05.20.726497

Preprint WatchMildMay 22nd, 2026

TKI-Tolerant Persisters Emerge from a PKCα-Dependent and Highly Plastic Subpopulation of Stem-Like Cells in NSCLC

Sadeghi, M.; Salama, M.; Choudhury, S.; Huang, A.; Yang, J.; Hannun, Y. A.

EGFR TKI-tolerant persisters in NSCLC emerge from a PKCalpha-dependent stem-like subpopulation rather than discrete on-target resistance mutations.

Mild contradiction

1 prior failure

One documented clinical failure (Phase 1 or 2) overlaps with the claimed mechanism.

The preprint identifies a PKCα-dependent stem-like subpopulation as the root of EGFR TKI-tolerant persisters in NSCLC, with the implication that osimertinib-driven persister cells survive through a non-mutational, plastic state rather than C797S-style on-target resistance. This refines, but does not contradict, the mechanistic story underlying bg-60366-egfr-cdac-nsclc-strategic-shutdown: an EGFR degrader still has to clear persister populations that do not require an EGFR-binding pocket, and any post-osimertinib program should pre-specify persister-state biomarkers in dose expansion.

Abstract excerpt

Reversible drug-tolerant persister states are emerging as key drivers of limited therapeutic durability, offering a complementary non-genetic perspective distinct from traditional models of acquired resistance. This is of particular interest in lung adenocarcinoma where EGFR tyrosine kinase inhibitors (TKIs) elicit dramatic responses, yet residual surviving cells persist and ultimately seed relapse. To define mechanisms that enable survival during this earliest residual-disease phase, we focused on the drug-tolerant persister population that remains after EGFR TKI exposure and can later give r

Matching Claidex post-mortems

1 of 1 indexed

May 22, 2026BG-60366 in EGFR-mutant NSCLC: a chimeric degrader retired after 33 patients in a saturated landscapeBG-60366SponsorMRS 16

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.